Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.46 Million EUR | -14.55% |
| 2022 | -8.52 Million EUR | -434.05% |
| 2021 | 2.55 Million EUR | 189.86% |
| 2020 | -2.84 Million EUR | 5.02% |
| 2019 | -2.99 Million EUR | -13.65% |
| 2018 | -2.63 Million EUR | -32.46% |
| 2017 | -1.98 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.83 Million EUR | 0.0% |
| 2024 Q1 | -1.83 Million EUR | 8.81% |
| 2023 Q2 | -4.4 Million EUR | -261.1% |
| 2023 FY | -9.76 Million EUR | -14.55% |
| 2023 Q3 | -2 Million EUR | 54.42% |
| 2023 Q1 | -1.22 Million EUR | 80.23% |
| 2023 Q4 | -2 Million EUR | 0.0% |
| 2022 Q2 | -6.9 Million EUR | -197.41% |
| 2022 Q4 | -6.17 Million EUR | -218.1% |
| 2022 FY | -8.52 Million EUR | -434.05% |
| 2022 Q1 | -2.32 Million EUR | -121.79% |
| 2022 Q3 | -1.94 Million EUR | 71.87% |
| 2021 Q2 | 2.32 Million EUR | 0.0% |
| 2021 Q1 | 2.32 Million EUR | 396.99% |
| 2021 FY | 2.55 Million EUR | 189.86% |
| 2021 Q4 | -1.04 Million EUR | 0.0% |
| 2021 Q3 | -1.04 Million EUR | -145.06% |
| 2020 Q2 | -638 Thousand EUR | 0.0% |
| 2020 Q1 | -638 Thousand EUR | 0.0% |
| 2020 FY | -2.84 Million EUR | 5.02% |
| 2020 Q4 | -782 Thousand EUR | 0.0% |
| 2020 Q3 | -782 Thousand EUR | -22.57% |
| 2019 FY | -2.99 Million EUR | -13.65% |
| 2018 FY | -2.63 Million EUR | -32.46% |
| 2017 FY | -1.98 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -89.361% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 94.928% |
| Adocia SA | -17.62 Million EUR | 63.336% |
| Biophytis S.A. | -14.33 Million EUR | 54.922% |
| Advicenne S.A. | -6.45 Million EUR | -0.062% |
| genOway Société anonyme | 2.06 Million EUR | 412.837% |
| IntegraGen SA | -183.77 Thousand EUR | -3415.808% |
| Medesis Pharma S.A. | -4.22 Million EUR | -52.766% |
| Neovacs S.A. | -6.9 Million EUR | 6.465% |
| NFL Biosciences SA | -4.43 Million EUR | -45.833% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -730.21% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -105.944% |
| Sensorion SA | -22.31 Million EUR | 71.041% |
| Theranexus Société Anonyme | -7.64 Million EUR | 15.473% |
| TME Pharma N.V. | -5.62 Million EUR | -14.883% |
| Valbiotis SA | -7.16 Million EUR | 9.763% |
| TheraVet SA | -2.17 Million EUR | -197.043% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 68.154% |
| argenx SE | -417.15 Million EUR | 98.451% |
| BioSenic S.A. | -7.04 Million EUR | 8.224% |
| Celyad Oncology SA | -8.45 Million EUR | 23.602% |
| DBV Technologies S.A. | -85.24 Million EUR | 92.421% |
| Galapagos NV | -88.26 Million EUR | 92.68% |
| Genfit S.A. | -26.58 Million EUR | 75.692% |
| GeNeuro SA | -14.35 Million EUR | 54.999% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 59.601% |
| Innate Pharma S.A. | -12.66 Million EUR | 49.001% |
| Inventiva S.A. | -102.7 Million EUR | 93.709% |
| MaaT Pharma SA | -19.94 Million EUR | 67.603% |
| MedinCell S.A. | -20.97 Million EUR | 69.2% |
| Nanobiotix S.A. | -26.77 Million EUR | 75.873% |
| Onward Medical N.V. | -35.46 Million EUR | 81.781% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -42.025% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 71.892% |
| Oxurion NV | -12.11 Million EUR | 46.647% |
| Pharming Group N.V. | -4.87 Million EUR | -32.41% |
| Poxel S.A. | -28.76 Million EUR | 77.538% |
| GenSight Biologics S.A. | -29.69 Million EUR | 78.243% |
| Transgene SA | -30.01 Million EUR | 78.472% |
| Financière de Tubize SA | -2.14 Million EUR | -201.356% |
| UCB SA | 604 Million EUR | 101.07% |
| Valneva SE | -82.08 Million EUR | 92.129% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 77.595% |